Open Nav

Biologics: Billions from BioBetters?

Tuesday, October 25th, 2:00pm-2:55pm, Twin Peaks North/South

With patent expirations looming, pharma, large and small biotech are scrambling for “the next big thing.” An approval pathway for biosimilars is underway, with guidance from the Agency anticipated soon.  What are the opportunities for new competitive products and even blockbusters? The question is who and with what technology? In the ultra-competitive space of biosimilars, selling a market clone may not be enough and will some companies seek to develop a biobetter or biosuperior?  Panelists will differentiate products on the horizon and outline winning  strategies for market penetration.


  • Ronald W. Lennox, DPhil, Partner & Founder, CHL Medical Partners


  • Dee Athwal, Fourteen22
  • Stephen Keane, President & COO, Femta Pharmaceuticals, Inc.
  • Douglas B. Neely, CMPE, MHA, Senior Director, Oncology Market Insights, Xcenda
  • William J. Newell, Chief Executive Officer, Sutro Biopharma, Inc.

Who's Who  


Stephen Keane - Stephen Keane brings to Femta more than 20 years of experience in the biotechnology industry during which he has negotiated acquisitions and numerous strategic corproate alliances, established joint ventures and lead public and private financings. He has held senior positions with Ambit Biosciences, Dendreon Corp., Corvas International, Epimmune, Inc, SIBA Neurosciences and Molecular Biosystems.

Ronald W. Lennox - Ron invests in the biotechnology and molecular diagnostic sectors. He has served on the boards of eighteen companies including General Surgical Innovations, Inc. (acquired by Tyco International Corp.), GeneOhm Sciences, Inc. (acquired by Becton Dickinson), Protometrix, Inc. (acquired by Invitrogen Corp.), and Applied Molecular Evolution Inc. (acquired by Eli Lilly). He was founding CEO of Protometrix, Inc. as well as of CGI Pharmaceuticals, Inc.

Prior to the founding of CHL Medical Partners, Ron was a general partner at Hancock Venture Partners (now HarbourVest Partners) where he invested in sixteen healthcare companies, ten of which had successful IPOs.

Ron graduated from the University of Glasgow with a B.Sc. in Molecular Biology, Oxford University where he received a D.Phil. in Cell Biology and the Wharton School of the University of Pennsylvania.  

Doug B. Neely - Mr. Neely is a Senior Director within the Customer Relations team. In this role, he helps manufacturers design and implement effective commercialization access strategies for oncology products and other specialty products.

Mr. Neely brings more than 17 years of experience in healthcare, with 10 years focused on the provider side of the industry. He combines his firsthand experience working inside physician practices and hospitals with his knowledge of patient and provider support programs to offer clients a real-world perspective of the challenges facing prescribers today. He is an experienced presenter (including the ACCC Annual Meeting and MGMA/AOHA) and has authored publications on reimbursement and access topics both in general and specifically related to oncology products.

A Certified Medical Practice Executive (CMPE) through the American College of Medical Practice Executives, Mr. Neely earned an MHA from the Medical College of Virginia / Virginia Commonwealth University and a BA from Wake Forest University.

William J. Newell - Mr. Newell has over 10 years of senior management experience in the biotechnology industry. He joined Sutro Biopharma as CEO in January 2009. Previously, he served as the President of Aerovance, Inc., a venture-backed company developing clinical assets for respiratory diseases. Mr. Newell also was Chief Business Officer and Senior Vice President at publicly-traded QLT, Inc. and served in several senior management positions at public-traded Axys Pharmaceuticals, Inc, where he ultimately served as Senior Vice President, Corporate and Business Development prior to Celera Genomics’s acquisition of Axys. For the 15 years prior to joining Axys, Mr. Newell practiced law at the law firm of Bingham McCutchen LLP.